Anti-factor Xa levels in obese patients receiving enoxaparin for treat | CPAA
Dose capping of enoxaparin results in sub-therapeutic anti-Xa level - The British Journal of Cardiology
JCM | Free Full-Text | Monitoring of Unfractionated Heparin Therapy in the Intensive Care Unit Using a Point-of-Care aPTT: A Comparative, Longitudinal Observational Study with Laboratory-Based aPTT and Anti-Xa Activity Measurement
JCM | Free Full-Text | Monitoring of Unfractionated Heparin Therapy in the Intensive Care Unit Using a Point-of-Care aPTT: A Comparative, Longitudinal Observational Study with Laboratory-Based aPTT and Anti-Xa Activity Measurement
Target Anti-Xa Ranges | Download Table
![PDF] Anticoagulation in special patient populations: are special dosing considerations required? | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5a17d307572530f65200781b2f95026e9de86134/2-Table1-1.png "PDF] Anticoagulation in special patient populations: are special dosing considerations required? | Semantic Scholar")
PDF] Anticoagulation in special patient populations: are special dosing considerations required? | Semantic Scholar
Biomedicines | Free Full-Text | Updates in Anticoagulation Therapy Monitoring | HTML
Weight-based enoxaparin with anti-factor Xa assay-based dose adjustment for venous thromboembolic event prophylaxis in adult trauma patients results in improved prophylactic range targeting | SpringerLink
Interpretation of anti-Xa levels in patients on LMWH | Download Table
View of Measuring Anti–Factor Xa Activity to Monitor Low-Molecular-Weight Heparin in Obesity: A Critical Review | Canadian Journal of Hospital Pharmacy
Target Anti-Xa Ranges | Download Table
JCM | Free Full-Text | Monitoring of Unfractionated Heparin Therapy in the Intensive Care Unit Using a Point-of-Care aPTT: A Comparative, Longitudinal Observational Study with Laboratory-Based aPTT and Anti-Xa Activity Measurement
Anti-Xa guided enoxaparin dose adjustment improves pharmacologic deep venous thrombosis prophylaxis in burn patients - ScienceDirect
PDF) Measuring Anti–Factor Xa Activity to Monitor Low-Molecular-Weight Heparin in Obesity: A Critical Review
Article: No accumulation of a prophylactic dose of nadroparin in moderate renal insufficiency (full text) - October 2015 - NJM
Target Anti-Xa Ranges | Download Table
Unfractionated heparin (UFH), LMWH, fondaparinux, argatroban, and bivalirudin - EMCrit Project
Article: Dalteparin and anti-Xa: a complex interplay of therapeutic drug monitoring (full text) - December 2019 - NJM
Article: No accumulation of a prophylactic dose of nadroparin in moderate renal insufficiency (full text) - October 2015 - NJM
An Evaluation of the Basis for Anti-Xa Testing in Patients on Low Molecular Weight Heparin and its Impact on Subsequent Management - ISTH Congress Abstracts
An Evaluation of the Basis for Anti-Xa Testing in Patients on Low Molecular Weight Heparin and its Impact on Subsequent Management - ISTH Congress Abstracts
Variation in anti-factor Xa over time for each dose of enoxaparin .... | Download Scientific Diagram
